Heat Biologics, Inc. (NASDAQ:HTBX) shares shot up 2.5% on Friday . The stock traded as high as $0.77 and last traded at $0.77. 706,969 shares changed hands during trading, an increase of 77% from the average session volume of 399,411 shares. The stock had previously closed at $0.75.

Several brokerages have recently weighed in on HTBX. Noble Financial reissued a “buy” rating on shares of Heat Biologics in a research report on Tuesday, July 4th. ValuEngine cut shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Zacks Investment Research cut shares of Heat Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Griffin Securities began coverage on shares of Heat Biologics in a research report on Tuesday, September 12th. They set a “buy” rating and a $2.25 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $2.13.

The stock’s market cap is $27.16 million. The firm’s 50-day moving average is $0.59 and its 200 day moving average is $0.65.

A number of institutional investors have recently bought and sold shares of HTBX. KCG Holdings Inc. increased its position in Heat Biologics by 35.3% during the 1st quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 45,831 shares in the last quarter. Sabby Management LLC purchased a new stake in Heat Biologics during the 1st quarter worth about $2,176,000. Finally, Vanguard Group Inc. increased its position in Heat Biologics by 11.9% during the 2nd quarter. Vanguard Group Inc. now owns 661,388 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 70,290 shares in the last quarter. Hedge funds and other institutional investors own 8.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/08/heat-biologics-inc-htbx-shares-up-2-5.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Stock Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related stocks with our FREE daily email newsletter.